First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis

First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis

Background: Patients with HER2-negative locally advanced or unresectable metastatic gastric cancer and gastroesophageal junction (G/GEJ) adenocarcinoma have limited first-line treatment options and a poor prognosis. The GLOW clinical trial showed that zolbetuximab plus capecitabine plus oxaliplatin...

Full description

Saved in:
Bibliographic Details
Main Authors: Jianying Lei, Jiahao Zhang, Caicong You, Wu Fu, Maobai Liu, Na Li
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848241297052
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items